Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.19 | N/A | +19.97% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.19 | N/A | +19.97% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about the company's clinical developments. They noted that while they are making progress, there are still challenges ahead.
Management highlighted progress in their clinical pipeline.
They emphasized the importance of upcoming trials for future growth.
Biocryst Pharmaceuticals reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising 3.59%. The lack of revenue data and guidance indicates uncertainty about future performance. Investors may be encouraged by the company's progress in clinical trials, but the absence of specific guidance leaves some questions unanswered.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WILLIS TOWERS WATSON
Aug 6, 2018